Bristol-Myers: shares down after mixed phase III study.
(CercleFinance.com) - A combination of Opdivo and Yervoy did not reach statistical significance in the treatment of renal cell carcinoma in a phase-3 study, Bristol-Myers Squibb said on Wednesday.
While there was an improvement in progression-free survival (PFS), the median PFS was 11.56 months for the Opdivo and Yervoy combination versus 8.38 months for Pfizer's sunitinib.
This was despite the combination meeting the co-primary endpoint of objective response rate (ORR) by achieving a 41.6% ORR versus 26.5% for sunitinib, the drugmaker said.
Bristol-Myers Squibb said it was encouraged by these results and said that the study will continue as planned.
Its shares were down 0.8% at 57.4 dollars after these comments were made.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
While there was an improvement in progression-free survival (PFS), the median PFS was 11.56 months for the Opdivo and Yervoy combination versus 8.38 months for Pfizer's sunitinib.
This was despite the combination meeting the co-primary endpoint of objective response rate (ORR) by achieving a 41.6% ORR versus 26.5% for sunitinib, the drugmaker said.
Bristol-Myers Squibb said it was encouraged by these results and said that the study will continue as planned.
Its shares were down 0.8% at 57.4 dollars after these comments were made.
Copyright (c) 2017 CercleFinance.com. All rights reserved.